Tramadol and Alecensa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tramadol (tramadol hydrochloride) and Alecensa (alectinib hydrochloride). Common drug interactions include seizure among females and interstitial lung disease among males.

The phase IV clinical study analyzes what interactions people have when they take Tramadol and Alecensa. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Tramadol?

Tramadol has active ingredients of tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 235,800 Tramadol users. Check the latest studies of Tramadol.

What is Alecensa?

Alecensa has active ingredients of alectinib hydrochloride. eHealthMe is studying from 5,132 Alecensa users. Check the latest studies of Alecensa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

35 people who take Tramadol and Alecensa together, and have interactions are studied.

Tramadol and Alecensa drug interactions.

What are the common drug interactions of Tramadol and Alecensa, by gender? *:

female:

  1. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  2. Death
  3. Pyrexia (fever)
  4. Vertigo
  5. Vision blurred
  6. Vomiting
  7. Bradycardia (abnormally slow heart action)
  8. Cerebral disorder (brain disease)
  9. Confusional state
  10. Dehydration (dryness resulting from the removal of water)

male:

  1. Interstitial lung disease
  2. Nausea (feeling of having an urge to vomit)
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Atrioventricular block complete (heart block complete)
  5. Atrioventricular block first degree (heart block first degree)
  6. Diarrhoea
  7. Disease progression
  8. Dyspnoea (difficult or laboured respiration)
  9. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  10. Lung carcinoma cell type unspecified stage iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver)

What are the common drug interactions of Tramadol and Alecensa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Rash

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Constipation
  2. Nausea (feeling of having an urge to vomit)
  3. Death
  4. Pyrexia (fever)
  5. Vertigo
  6. Vision blurred

60+:

  1. Interstitial lung disease
  2. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  3. White blood cell count decreased
  4. Bradycardia (abnormally slow heart action)
  5. Cerebral disorder (brain disease)
  6. Confusional state
  7. Depressed level of consciousness
  8. Pyrexia (fever)
  9. Asthenia (weakness)
  10. Atrioventricular block complete (heart block complete)

What are the existing conditions these people have? *

  1. Lung Neoplasm Malignant (cancer tumour of lung): 14 people, 40.00%
  2. Lung Adenocarcinoma (a form of non-small cell lung cancer): 7 people, 20.00%
  3. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 6 people, 17.14%
  4. High Blood Pressure: 6 people, 17.14%
  5. Nausea (feeling of having an urge to vomit): 4 people, 11.43%
  6. Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 8.57%
  7. Neoplasm Malignant (cancer tumour): 3 people, 8.57%
  8. Bronchial Carcinoma (lung cancer): 3 people, 8.57%
  9. Stomatitis (inflammation of mucous membrane of mouth): 2 people, 5.71%
  10. Rashes (redness): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Tramadol and Alecensa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tramadol and Alecensa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tramadol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Alecensa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tramadol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Alecensa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on tramadol hydrochloride and alectinib hydrochloride (the active ingredients of Tramadol and Alecensa, respectively), and Tramadol and Alecensa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: